A large European consortium has joined forces to deliver new vaccine candidates against tuberculosis (TB). The identification of promising vaccination antigens and disease-specific biomarkers could improve the dismal prognosis of TB in the near future.
TB constitutes one of the deadliest infectious diseases worldwide with millions of deaths every year. Although the causative agent Mycobacterium tuberculosis (MTB) can be treated with antibiotics to some extent, the emergence of drug-resistant bacterial strains hampers the effectiveness of the treatment.